The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Challenges in utilizing mutation testing in AML
Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the challenges and feasibility of mutation testing in acute myeloid leukemia (AML). Some institutions lack resources for these techniques, and even in well-equipped centers, testing can be time-consuming, so surrogates for genetic profiling can be used. Dr Loghavi notes that treatment with menin or IDH inhibitors can induce differentiation and apoptosis in mutated cells. Thus, there is a need for methods to distinguish between these differentiated cells destined to die and leukemic blasts. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
